Literature DB >> 27630317

Diaphragmatic Surgery in Advanced Ovarian, Tubal and Peritoneal Cancer. A 7-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.

Mustafa Zelal Muallem1, Jumana Almuheimid2, Rolf Richter2, Elena Ioana Braicu3, Suzan Osman4, Jalid Sehouli2.   

Abstract

AIM: This study aimed to analyze diaphragmatic interventions and their complications in primary cytoreductive surgery (PCS) and to study their impact on attaining complete tumor resection (CTR) in advanced ovarian cancer (AOC), which is purportedly reflected in better disease-free and overall survival. PATIENTS AND METHODS: The study's collective consisted of 536 consecutive patients presenting a first diagnosis of AOC who underwent PCS between 2007 and 2013 at the Charité Medical University, Berlin. A total of 268 patients underwent diaphragmatic interventions, while 268 did not undergo any kind of diaphragmatic surgery.
RESULTS: Diaphragmatic interventions were indicated in 50% of cases with AOC. The surgical interventions varied between diaphragmatic partial resection (44.8%), stripping (53%) and only infrared coagulation (2.2%). The postoperative complication rate was higher in the diaphragm-intervention group in comparison to the group without any diaphragmatic intervention (49.6% vs. 38.8%), but most postoperative complications were not directly related to the diaphragmatic intervention itself but to the statically significant increase of other radical surgical procedures in this group. Pleura effusion was the only increased complication with a direct correlation with diaphragmatic surgery (25.4% vs. 14.2%). Preoperatively apparent stage IV (pleura effusion) disease, very high cancer antigen-125 value, serous papillary tumors and the presence of massive ascites (>500 ml) were statistically significant predictors of the need for diaphragmatic surgery in order to achieve CTR.
CONCLUSION: Our current findings consider diaphragmatic surgery as being acceptable, feasible and in many cases as an essential intervention to achieve CTR or suboptimal debulking with an acceptable complication rate. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Advanced ovarian cancer; debulking; diaphragmatic surgery

Mesh:

Substances:

Year:  2016        PMID: 27630317     DOI: 10.21873/anticanres.11025

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Application of J-Plasma in the excision of diaphragmatic lesions as part of complete cytoreduction in patients with advanced ovarian cancer.

Authors:  Vasilios Theodoulidis; Anastasia Prodromidou; Emmanouil Stamatakis; Nicholas Alexakis; Alexandros Rodolakis; Dimitrios Haidopoulos
Journal:  Mol Clin Oncol       Date:  2022-05-18

2.  Retrospective Analysis of Total Parietal Peritonectomy Without Systematic Lymphadenectomy for Advanced Epithelial Ovarian Cancer.

Authors:  Suguru Odajima; Hiroshi Tanabe; Yuki Koike; Kota Yokosu
Journal:  Cancer Diagn Progn       Date:  2022-07-03

3.  Association of Diaphragmatic Surgery as Part of Cytoreductive Effort in Advanced Stage Ovarian Cancer.

Authors:  Nicolae Bacalbasa; Irina Balescu; Cristian Balalau; Olivia Ionescu; Claudia Stoica
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

4.  A Promising Approach for Primary Cytoreductive Surgery for Advanced Ovarian Cancer: Survival Outcomes and Step-by-Step Description of Total Retroperitoneal en-Bloc Resection of Multivisceral-Peritoneal Packet (TROMP).

Authors:  Mustafa Zelal Muallem; Luisa Kluge; Ahmad Sayasneh; Jalid Sehouli; Dario Zocholl; Jumana Muallem; Andrea Miranda
Journal:  J Pers Med       Date:  2022-05-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.